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Abstract
Biomarkers aid the study of osteoarthritis (OA) in a number of
different ways. In this article we summarise briefly their multiple
uses and reflect on how the study reported in a previous edition of
Arthritis Research & Therapy should promote further investigation
of cartilage oligomeric matrix protein (COMP). COMP is foremost
among hitherto investigated biomarkers and is most consistently
shown to predict knee OA progression. Precisely what role it plays
in OA pathogenesis remains unclear and elucidating this may be
key to defining, and then targeting, the cellular pathways involved
in OA.
The field of osteoarthritis (OA) study is desperately in need of
biomarkers. A sound biomarker could alter radically OA
prediction, OA management, trials of therapies and our
understanding of disease pathogenesis. Biomarkers are
generally considered to be biological substances, although
some workers view imaging and even traditional disease risk
factors as biomarkers. In the present article, we shall consider
only biological substances, which include proteins, RNA and
DNA. Biomarkers may be used in isolation, in combination
with each other or even in combination with imaging to
provide more information about OA.
OA is a highly prevalent, age-related degenerative disease of
synovial joints whose hallmark is cartilage loss. Although
great strides have been made in the past decade to further
the understanding of cartilage loss, subchondral bone abnor-
malities and the extra-articular inflammation of tendons and
ligaments, there are still no disease-modifying agents for the
treatment of OA. Current therapies are generally palliative,
with analgesics, weight loss and muscle-strengthening
exercises forming the bedrock of management before joint
replacement is used. Generally, the favoured methods of OA
assessment are imaging based, with plain radiographs widely
used and magnetic resonance imaging (MRI), which remains
relatively expensive, used much less. Plain films, however,
relate poorly to patient symptoms, and abnormalities occur
relatively late in disease. It is increasingly recognised that the
very earliest pathological changes take place periarticularly,
and are not captured well by plain film but are evident on MRI.
A biomarker detectable very early in disease that could be
measured in blood or urine would enhance our ability to
detect early OA, would allow prognostication, and would be
of great value to those conducting pharmaceutical trials of
new agents. Such a biomarker would also help to shed light
on the pathogenic mechanisms underlying the early stages of
OA.
With this knowledge in mind, the Boston Osteoarthritis Knee
Study group has looked at the relationship between MRI
changes at the knee and a number of markers of cartilage
turnover [1]. The group hypothesised that increased levels of
cartilage degradation products and/or imbalance of cartilage
synthesis and degradation markers would be predictive of
subsequent cartilage loss.
Disappointingly, of the biomarkers studied only the baseline
level of cartilage oligomeric matrix protein (COMP) was
predictive of subsequent MRI-determined cartilage loss in the
OA knee. For each unit increase in COMP, the authors report
a sixfold increased odds of cartilage loss, even after
adjustment for the known risk factors – age and body mass
index [1]. COMP is a 435,000 Da pentameric member of the
thrombospondin protein family. It was isolated initially from
cartilage, is synthesised by chondrocytes and is present in
small amounts in the synovium and tendon as well as being
detectable in serum [2]. COMP is abundant in OA cartilage.
Previous studies have shown that serum COMP levels
predict progression of disease in both subjects with
radiographic knee OA at baseline [3] and those with knee
pain and normal baseline knee X-ray [4]. The findings from
the Boston Osteoarthritis Knee Study group complement
what has been shown before [5]. COMP is going to be
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helpful in selecting patients at high risk for cartilage loss for
recruitment into clinical trials: more rapid assessment of the
efficacy of a disease-modifying drug will be possible, and
anything that helps facilitate clinical trials is a good thing. In
addition, this finding and others may shed further light on the
pathogenesis of OA. Serum COMP is known to be
independently heritable [6], and further exploration of the
genes controlling this may reveal new pathways in early OA
pathogenesis, or indeed provide a better surrogate marker, as
COMP levels are known to fluctuate nonlinearly over time [7].
Whether the elevated serum COMP levels are influenced by
COMP released from ligaments and tendons – the very
structures increasingly recognised as being involved in early
disease [8] – will be an important question to answer.
Why did no other biomarkers, many of which were derived
from collagen, show association? One problem in this area is
that collagen products probably reflect activity in all tissues
over the whole body (including other joints, bone and inter-
vertebral disc), not just in the affected knee chosen for
imaging. Add to this the wide day-to-day variation in many of
the biomarkers measured, and picking up early changes in
systemic levels of collagen-derived biomarkers seems
unlikely. As the authors mention, it may be that the chosen
specific endpoint of MRI cartilage loss was the problem here:
perhaps bone marrow lesions would have had a stronger
association. The most surprising finding occurs with collagen
II crosslinking C-telopeptide, which has been shown to be
associated in a number of previous studies mainly using X-ray
data. These results may reflect the temporal nature of
cartilage destruction in OA: using MRI, early cartilage
damage is detected in which COMP and aggrecan are
released. Collagen II degradation, as detected by collagen II
crosslinking C-telopeptide, may come later.
Rather than dwell on disappointing collagen-derived markers,
we should celebrate the positive. Evidence is accumulating
that COMP predicts MRI cartilage loss and appears a useful
biomarker of early OA. It will have many uses and, if more
ammunition were needed, this paper should stimulate serious
research into COMP's behaviour, shedding light on early
pathogenic pathways, as well as determining its clinical
usefulness as a biomarker.
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